Summary
A series of continuous human tumour cell lines, derived from various tumour types, were used to establish whether the combination of spirogermanium (SP) with other ‘standard’ antitumour drugs proved superior to these as single agents in reducing cell survival in vitro. A non-cytotoxic concentration of SP was selected and when combined with a range of concentrations of cisplatin or 5-fluorouracil (5-FU), definite synergistic cell kill was noted in all lines tested. In contrast, the combination of SP with various other antitumor drugs, including adriamycin, methotrexate and the vinca alkaloids and with X-irradiation did not enhance cytotoxicity.
These pre-clinical in vitro studies suggest that benefit may accrue from combining SP with either 5-FU or cisplatin and provide a basis for their clinical evaluation in colo-rectal tumours or transitional cell cancer of the bladder, respectively.
Similar content being viewed by others
References
Rice LM, Wheeler JW, Geschickter CF: Spirans XXII. Synthesis of 4,4-dialkyl-4-germacyclohexanone and 8,8-dialkyl-8-germaazaspiro (4,5) decanes. J Heterocycl Chem 11:1041–1946, 1974
Schein PS, Slavik M, Smyth T, Hoth D, Smith F, MacDonald JS, Wooley PV: Phase I clinical trial of spirogermanium. Cancer Treat Rep 64:1051–1056, 1980
Mattsson W: A phase I study of spirogermanium. (Abstract) Proc Am Assoc Cancer Res 21:194, 1980
Budman DR, Schulman P, Vinciguerra V, Degman T: A phase I trial of spirogermanium given by infusion in a multiple-dose schedule. Cancer Treat Rep 66:173–175, 1982
Weiselberg L, Budman DR, Schulman P, Vinciguerra W, Degman TJ, Pasmantier M: Phase II trial of spirogermanium in advanced epithelial carcinoma of the ovary. Cancer Treat Rep 66:1675–1676, 1982
Budman DR, Ginsberg S, Perry M, Weinberg V, Schein P, Hanson J, Coleman M, Wood W: Phase II trial of spirogermanium in breast adenocarcinoma: a cancer and leukemia group B study. Cancer Treat Rep 66:1667–1668, 1982
Falkson G, Falkson HC: Phase II trial of spirogermanium for advanced breast cancer. Cancer Treat Rep 67:189–190, 1983
Legha SS, Ajani JA, Bodey GP: Phase I study of spirogermanium given daily. J Clin Oncol 1:331–336, 1983
Mulinos MG, Amin P: Toxicology and phase I study of a new anticancer agent, spirogermanium HCl. Fed Proc 39:747, 1980
Yang S-J, Rafla S: Effect of spirogermanium on V79 Chinese hamster cells. Am J Clin Oncol 5:331–337, 1983
Hill BT, Whatley SA, Bellamy AS, Jenkins LY, Whelan RDH: Cytotoxic effects and biological activity of 2-aza-8-germanspiro-[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro. Cancer Res 42:2852–2856, 1982
Hill BT, Metcalfe SA, Hepburn PJ, Masters JRW, Whelan RDH: Evaluation of spirogermanium in murine and human tumour lines in vitro and demonstration of synergy with cisplatin or 5-fluorouracil. Proceedings of 13th International Congress of Chemotherapy, Vienna. Part 257, 30–33, 1983
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterisation of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16–23, 1979
Hill BT, Whelan RDH: Attempts to optimise colony-forming efficiencies using three different survival assays and a range of human tumour continuous cell lines. Cell Biol Int Rep 7:617–624, 1983
Hastings RJ, Franks LM: Chromosome pattern, growth in agar and tumorigenicity in nude mice of four human bladder carcinoma cell lines. Int J Cancer 27:15–21, 1983
Horwitz KB, Costlow ME, McGuire WL: A human breast cancer cell line with estrogen, androgen, progesterone and glucocorticoid receptors. Steroids 26:785–795, 1975
Alberts DS, Chen H-SG: Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: SE Salmon (ed): Cloning of Human Tumor Stem Cells. Alan R Liss Inc, New York, 1980, pp 351–359
Hill BT, Whelan RDH, Rupniak HT, Dennis LY, Rosholt MA: A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. Cancer Chemother Rep 7:21–26, 1981
Rupniak HT, Whelan RDH, Hill BT: Concentration and time-dependent inter-relationships for antitumors drug cytotoxicities against tumour cells in vitro. Int J Cancer 32:7–12, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hill, B.T., Bellamy, A.S., Metcalfe, S. et al. Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro . Invest New Drugs 2, 29–33 (1984). https://doi.org/10.1007/BF00173784
Issue Date:
DOI: https://doi.org/10.1007/BF00173784